Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Algeria has been experiencing significant growth in recent years.
Customer preferences: Algerian consumers have been showing a growing preference for locally produced pharmaceuticals, as they tend to be more affordable than imported brands. This trend has been driven by the government's efforts to increase domestic production and reduce reliance on imports. Additionally, there is a growing demand for generic drugs, which are seen as more cost-effective alternatives to branded medications.
Trends in the market: One of the key trends in the Algerian Pharmaceuticals market is the increasing focus on research and development. Local companies are investing heavily in R&D to develop new drugs and improve existing ones, in order to meet the growing demand for high-quality pharmaceuticals. Another trend is the increasing adoption of digital technologies, such as telemedicine and e-prescriptions, which are helping to improve access to healthcare services in remote areas.
Local special circumstances: Algeria has a large and growing population, which is driving demand for healthcare services and pharmaceuticals. However, the country's healthcare infrastructure is still relatively underdeveloped, particularly in rural areas. This has created opportunities for companies to invest in the development of healthcare facilities and services, as well as the production and distribution of pharmaceuticals.
Underlying macroeconomic factors: Algeria's economy has been growing steadily in recent years, driven by strong performance in the oil and gas sector. This has led to increased government spending on healthcare and social services, which has helped to support the growth of the Pharmaceuticals market. Additionally, the government has implemented a number of policies aimed at promoting domestic production and reducing reliance on imports, which has created opportunities for local companies to expand their operations.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)